Wockhardt · NSE: WOCKPHARMA · BSE: 532300
Q3 FY22 results · Oct–Dec 2021
Wockhardt reported revenue from operations of ₹853.89 crore (up 11.8% from Q3 FY21) and net profit of ₹1.77 crore (down 94.5% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 853.89 | 764.02 | +11.8% | 862.00 | −0.9% |
| Other income | 2.05 | 100.54 | −98.0% | 5.20 | −60.6% |
| Total income | 855.94 | 864.56 | −1.0% | 867.20 | −1.3% |
| Profit before tax | (28.56) | 31.19 | Turned loss | (29.24) | Loss narrowed |
| Net profit for the period | 1.77 | 32.40 | −94.5% | 37.17 | −95.2% |
| Attributable to shareholders of the company | (6.78) | 15.24 | Turned loss | 33.53 | Turned loss |
| EPS, basic (₹) | (0.61) | 1.38 | Turned loss | 3.03 | Turned loss |
| Net margin (%) | 0.2 | 4.2 | 4.3 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 308.61 | 252.97 | +22.0% | 310.44 | −0.6% |
| Other income | 3.01 | 9.72 | −69.0% | 4.19 | −28.2% |
| Total income | 311.62 | 262.69 | +18.6% | 314.63 | −1.0% |
| Profit before tax | (103.99) | (90.26) | Loss widened | (89.49) | Loss widened |
| Net profit for the period | (67.12) | (68.67) | Loss narrowed | (63.70) | Loss widened |
| EPS, basic (₹) | (6.06) | (6.20) | Loss narrowed | (5.75) | Loss widened |
| Net margin (%) | -21.7 | -27.1 | -20.5 |
Consolidated
- Filed with BSE
- 27 Jan 2022, 18:43 IST
- Board meeting
- 27 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jan 2022, 18:43 IST
- Board meeting
- 27 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE